New York State Teachers Retirement System Buys 14,489 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

New York State Teachers Retirement System lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 127,327 shares of the biopharmaceutical company’s stock after purchasing an additional 14,489 shares during the period. New York State Teachers Retirement System’s holdings in Halozyme Therapeutics were worth $7,288,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. TD Asset Management Inc lifted its holdings in shares of Halozyme Therapeutics by 28.1% during the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after purchasing an additional 557,350 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after purchasing an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Epoch Investment Partners Inc. boosted its position in shares of Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Halozyme Therapeutics by 9.7% during the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after purchasing an additional 72,544 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday. TD Cowen upped their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock worth $5,169,834 in the last quarter. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 2.3 %

NASDAQ:HALO opened at $58.47 on Tuesday. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 0.49 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The firm has a 50-day moving average price of $56.92 and a two-hundred day moving average price of $52.28.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 245.66%. The firm had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same quarter last year, the business posted $0.68 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.